• News
  • SAN DIEGO
  • BioTech

Isis Pharmaceuticals rises on strong 2Q results

Carlsbad-based Isis Pharmaceuticals Inc. said Monday its second-quarter loss narrowed, helped by a $25 million milestone payment from its development partner.

The results were better than Wall Street expected and Isis (Nasdaq: ISIS) shares jumped 8 percent in afternoon trading.

The company's loss totaled $1.2 million, or 1 cent per share, and compared with a loss of $17.9 million, or 18 cents per share, in the same quarter last year.

Revenue jumped 91 percent to $47.3 million from $24.8 million.

Analysts, on average, expected a loss of 10 cents per share on $40.1 million in revenue, according to a FactSet poll.

The recent quarter's revenue got a boost from a $25 million milestone payment the company received from the biotechnology company Genzyme when the Food and Drug Administration accepted the new drug application for Kynamro.

Kynamro is designed to treat a rare genetic condition that causes very high levels of “bad” LDL cholesterol. Isis and Genzyme filed for European Union marketing approval of the drug in July 2011, and they filed for U.S. approval in March 2012.

Isis has said it expects EU regulators to approve the drug before the end of 2012, and the FDA is scheduled to return a decision in late January.

The company ended the quarter with $336 million in cash.

Isis shares rose $1.11, or 9.1 percent, to close Monday at $13.19 , after peaking at $13.60 earlier in the session. Over the past 52 weeks, the company's shares have traded between $6.25 and $14.05.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing